@evaluatepharma profile picture
Evaluate Pharma @evaluatepharma

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2028 for the global life science industry.

Joined June 2009
  • Tweets 7,430
  • Following 706
  • Followers 6,979
3,335 Photos and videos
Which therapies will define the next decade of medicine? Daniel Chancellor and Melanie Senior look ahead to the drugs, therapy areas, and pipeline shaping 2032 in our World Preview 2026 webinar. Tuesday 16 June, 3pm BST. vist.ly/57pq8
A bold graphic featuring keyboard keys prompting registration. The vibrant design uses purple tones and encourages action in a direct, humorous way.

ALT A bold graphic featuring keyboard keys prompting registration. The vibrant design uses purple tones and encourages action in a direct, humorous way.
126
China's role in global pharma keeps growing. What does it mean for the US and Europe? Daniel Chancellor and Melanie Senior explore it in our World Preview 2026 webinar. Tuesday 16 June, 3pm BST. Register: vist.ly/57mic
Promotional image for World Preview 2026 event by Evaluate, featuring a digital theme with keyboard keys 'CTRL', 'ALT', and 'DATA' on a purple background.

ALT Promotional image for World Preview 2026 event by Evaluate, featuring a digital theme with keyboard keys 'CTRL', 'ALT', and 'DATA' on a purple background.
214
The 2026 World Preview report is packed with data. Daniel Chancellor and Melanie Senior bring the context behind the numbers in our World Preview 2026 Webinar. Tuesday 16 June, 3pm BST. Save your spot: vist.ly/57h92
A promotional image asking viewers if they have registered, featuring keys labeled 'Yes,' 'Also Yes,' and 'Do It Now' with a playful tone.

ALT A promotional image asking viewers if they have registered, featuring keys labeled 'Yes,' 'Also Yes,' and 'Do It Now' with a playful tone.
186
Where's biopharma heading by 2032? The top-selling drugs, the therapy areas driving growth, the future blockbusters, and the rise of China. Daniel Chancellor and Melanie Senior cover it in our World Preview 2026 webinar. Tuesday 16 June, 3pm BST. vist.ly/57cqi
Promotional image for Evaluate's World Preview 2026 event highlighting key deals in the pharmaceutical industry, featuring numeric keys and event details.

ALT Promotional image for Evaluate's World Preview 2026 event highlighting key deals in the pharmaceutical industry, featuring numeric keys and event details.
179
The global pharma market is forecast to top $2tn by 2032. What's behind that figure? Daniel Chancellor and Melanie Senior dig in at our World Preview 2026 webinar. Tuesday 16 June, 3pm BST. Register: vist.ly/579rb
Promotional graphic for Evaluate's World Preview event scheduled for June 16, 2026. Features a keyboard-themed motif symbolizing easy access to data insights.

ALT Promotional graphic for Evaluate's World Preview event scheduled for June 16, 2026. Features a keyboard-themed motif symbolizing easy access to data insights.
169
How do you move from reactive to proactive decision-making? In this expert interview, Ryan Lu unpacks how greater visibility across the development landscape is helping teams anticipate what’s next and act with confidence: vist.ly/56xj4
A consultant emphasizes the importance of visibility in staying ahead of market changes. The image features a professional, motivating tone with a corporate brand logo.

ALT A consultant emphasizes the importance of visibility in staying ahead of market changes. The image features a professional, motivating tone with a corporate brand logo.
183
Have you registered yet? Join Daniel Chancellor & Melanie Senior to explore top pharma trends, M&A, pipeline leaders, and more. đź“… June 16 | 3pm London | 10am New York Register now: vist.ly/56x72
A vibrant graphic prompting registration with three keyboard keys labeled 'Yes', 'Also Yes', and 'Do It Now'. The background is purple and features the word 'Evaluate' at the bottom.

ALT A vibrant graphic prompting registration with three keyboard keys labeled 'Yes', 'Also Yes', and 'Do It Now'. The background is purple and features the word 'Evaluate' at the bottom.
142
“My forecasting philosophy centers on two ideas: it’s both art and science, and the strongest forecasts combine models, judgment, and data.” Sheila Li on asset valuation, demand forecasting, and NPV across the product lifecycle: vist.ly/56p7y
A professional consultant in a business suit with text overlay about expert insights. The mood is professional and welcoming.

ALT A professional consultant in a business suit with text overlay about expert insights. The mood is professional and welcoming.
1
196
Tracking thousands of pharma assets manually is too slow and error-prone. Ryan Lu explains how we use proprietary data and expert validation to move from reactive to proactive decision-making. Get a clear view of the landscape here: vist.ly/56j3p
Professional headshot of Ryan Lu, a consultant at Evaluate, with a bold purple background and company branding. The image conveys professionalism and expertise.

ALT Professional headshot of Ryan Lu, a consultant at Evaluate, with a bold purple background and company branding. The image conveys professionalism and expertise.
165
The deal-making landscape is shifting fast. vist.ly/5677u 2025 saw $269.5B in alliances, $201B in M&A with mega deals, and $83.6B in financing—fewer deals, bigger bets. Medtech is rebounding, too.
Promotional graphic for a whitepaper on 2025 biopharma and medtech deal-making trends. Includes charts and download button.

ALT Promotional graphic for a whitepaper on 2025 biopharma and medtech deal-making trends. Includes charts and download button.
2
247
The World Preview 2026 webinar provides a clear view of the pharma landscape for the next 5 years, using industry-standard forecasting models trusted by leading investors and strategists. đź“… June 16 | 3pm London | 10am New York Register now: vist.ly/565uz
A promotional graphic for Evaluate's World Preview 2026 event. It features three keys labeled CTRL, ALT, and DATA, emphasizing data insights.

ALT A promotional graphic for Evaluate's World Preview 2026 event. It features three keys labeled CTRL, ALT, and DATA, emphasizing data insights.
1
204
Understanding what’s coming next in pharma starts with the right perspective. In our latest interview, Ryan Lu compiled the latest trends in upcoming drug approvals for a group purchasing organization. Dive into the interview for the complete insight: vist.ly/565ba
A professional headshot of Ryan Lu, a consultant from Evaluate, with a bold text overlay promoting his expertise. The mood is professional and informative.

ALT A professional headshot of Ryan Lu, a consultant from Evaluate, with a bold text overlay promoting his expertise. The mood is professional and informative.
179
What does it really take to stay ahead in today’s development landscape? In this expert interview, Ryan Lu breaks down how structured pipeline tracking and data-led analysis are helping organizations move from reactive to proactive decision-making: vist.ly/55syk
A professional consultant shares a quote about data-driven insights on a purple geometric background.

ALT A professional consultant shares a quote about data-driven insights on a purple geometric background.
166
Pre-ASCO signals are already here—oncology’s next phase is taking shape. From Datroway & Giredestrant to B7-H4 and bispecifics, our Pre-ASCO 2026 report highlights the assets and trends set to define the year ahead. Get ahead of the headlines: vist.ly/55r8t
A promotional graphic highlighting the 2026 Biomedtracker Datamonitor Healthcare Pre-ASCO report by Evaluate, set against a vibrant purple background. The image urges viewers not to wait for ASCO and invites them to download the report.

ALT A promotional graphic highlighting the 2026 Biomedtracker Datamonitor Healthcare Pre-ASCO report by Evaluate, set against a vibrant purple background. The image urges viewers not to wait for ASCO and invites them to download the report.
1
376
Biopharma entered 2026 with cautious optimism, but where do we actually stand? The data shows a complex picture: M&A surged in March and IPO activity paused after a fast start, while VC remains disciplined on risk. See the full Q1 picture: vist.ly/55kcw
Promotional image for a report on biopharma trends in Q1 2026. Features a digital theme with a focus on cautious industry navigation.

ALT Promotional image for a report on biopharma trends in Q1 2026. Features a digital theme with a focus on cautious industry navigation.
1
195
Billions in pharma sales are at risk as patents expire. Forecasting teams are key—shaping strategy from generics impact to portfolio priorities. See how their role is evolving: vist.ly/55g5u
198
Where are the biggest biopharma deals happening? vist.ly/55du8 Oncology leads (37% of partnerships), with autoimmune, immunology, and CNS gaining momentum. Billion-dollar alliances are focusing on these high-value areas.
Infographic on 2025 biopharma alliances, highlighting market trends and therapeutic area distribution. Bold colors and a bar chart define the visual layout.

ALT Infographic on 2025 biopharma alliances, highlighting market trends and therapeutic area distribution. Bold colors and a bar chart define the visual layout.
1
274
The future of pharma is changing fast. Get the clarity you need with the World Preview 2026 webinar, combining forecasts, competitive intelligence, and market data into one view of what is next. đź“… June 16 | 3pm London | 10am New York Secure your spot: vist.ly/55cwx
A bold 'Save the Date' graphic announcing the World Preview 2026 event on June 16th. The design features a striking purple theme with a calendar icon.

ALT A bold 'Save the Date' graphic announcing the World Preview 2026 event on June 16th. The design features a striking purple theme with a calendar icon.
1
217
From top‑selling drugs to the most valuable pipeline assets, here’s what will shape 2026. Explore the full Preview Report: vist.ly/55985
1
225
A good read from Fierce Biotech on how China-based biotechs are approaching pricing as buyers rely more on AI and local market insight. vist.ly/555dt Backed by Evaluate & @NorstellaCo data—worth a 5-min read. fiercebiotech.com/biotech/ch…

Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up

In an effort to defend its Keytruda kingdom, Merck & Co. | Chinese companies now represent 50% of global out-licensing deals, with U.S. companies dropping to about 28%, according to SynBioBeta data.

fiercebiotech.com
1
222
Load more